Tg Therapeuticscmn (NASDAQ:TGTX) has grabbed attention from the analysts, when it saw a value increase of 0% or 0 points in the last trading session to close at $10.15. A total of 1.3 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 1.67 Million shares, while its relative volume stands at 0.78. Tg Therapeuticscmn (NASDAQ:TGTX) has a market cap of $714.86 Million and the number of outstanding shares have been calculated 70.43 Million.
Shares of Tg Therapeuticscmn (NASDAQ:TGTX) currently have an Average Brokerage Recommendation of 1, number of Recs in ABR is 7 while industry rank of the company by ABR is 156 out of 265. Out of the analyst recommendations 4 rate Tg Therapeuticscmn (NASDAQ:TGTX) stock a Buy, 3 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $24.14 on the stock, this valuation is based on 7 number of opinions. The most optimistic analyst sees the stock reaching $30 while the most conventional has $15 target price.
In order to check on the sell-side rational, we can also take a peek at some technical indicators. Tg Therapeuticscmn (NASDAQ:TGTX)’s price sits -10.94% off from its 50-day moving average of $11.56 and 25.77% far from the stock’s 200-day moving average which is $8.91. Stock’s twelve month price oscillated between $15.35 and $4.10. The stock hit its twelve month high on 06/05/17, and twelve month low on 01/24/17. The Average True Range, a measure of volatility is at 0.75, however its weekly and monthly volatility is 4.49%, 6.38% respectively. The company’s Relative Strength Index which shows price strength currently stands at 40.81.
Tg Therapeuticscmn (NASDAQ:TGTX) as of recent trade, has shown weekly downbeat performance of -8.14% which was maintained at -21.92% in 1-month period. During the past three months the stock slid -8.14%, bringing six months performance to 128.09%. Yearly performance of the stock shows a bullish trend of 69.17% while year-to-date (YTD) performance reflected 118.28% positive outlook.
While taking a glance at financials, we can look at a number of key indicators. Tg Therapeuticscmn (NASDAQ:TGTX) has trailing twelve month Return on Assets of -105.7%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -135.3% and a Return on Investment of 0%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Tg Therapeuticscmn (NASDAQ:TGTX) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Tg Therapeuticscmn (NASDAQ:TGTX)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 1.21.
The company’s quick ratio for most recent quarter is 6 along with current ratio for most recent quarter of 6. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.